发明公开
- 专利标题： PYRIMIDINONES AS FACTOR XIA INHIBITORS
- 专利标题（中）： 嘧啶类作为因子XIA抑制剂
-
申请号： EP17189935.4申请日： 2015-07-29
-
公开(公告)号： EP3293186A1公开(公告)日： 2018-03-14
- 发明人: DILGER, Andrew K. , CORTE, James R. , DE LUCCA, Indawati , FANG, Tianan , YANG, Wu , WANG, Yufeng , PABBISETTY, Kumar Balashanmuga , EWING, William R. , ZHU, Yeheng , WEXLER, Ruth R. , PINTO, Donald J.P. , ORWAT, Michael J. , SMITH II, Leon M.
- 申请人： Bristol-Myers Squibb Company
- 申请人地址： Route 206 and Province Line Road Princeton, NJ 08543-4000 US
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： Route 206 and Province Line Road Princeton, NJ 08543-4000 US
- 代理机构： Kling, Edouard
- 优先权： US201462058316P 20141001
- 主分类号： C07D471/18
- IPC分类号： C07D471/18 ; A61K31/4162 ; A61P7/02
摘要：
The present invention provides compounds of Formula (I):
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
公开/授权文献
- EP3293186B1 PYRIMIDINONES AS FACTOR XIA INHIBITORS 公开/授权日：2020-09-23
信息查询
